| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 199.83 | 37.8% | 20.3% |
| Total Income | 202.56 | 37.1% | 20.1% |
| Expenditure | 134.24 | 33.8% | 26.0% |
| PBT | 68.32 | 44.1% | 10.1% |
| Net Profit | 50.43 | 45.0% | 9.3% |
| OPM | 36.35% | 0.71pp | 3.61pp |
| NPM | 24.90% | 1.35pp | 2.47pp |
| EPS | 6.27 | 45.1% | 9.8% |
Supriya Lifescience Ltd. Approves Unaudited Financial Results for Q2 and H1 of FY2025-2026
12 Nov 2025 · 12 Nov 2025, 05:13 pm
Summary
The Board of Directors of Supriya Lifescience Ltd. approved the Unaudited Financial Results for the quarter and half year ended September 30, 2025. The revenue from operations for the quarter ended September 30, 2025, is 1,998.33 million. The total income for the same period is 2,025.58 million. The earnings per equity share for continuing operations is 6.27 for both basic and diluted.
Key Highlights
- 1
Q2 and H1 of FY2025-2026 financial results approved
- 2
Revenue from operations for Q2 FY2025-2026 is 1,998.33 million
- 3
Total income for Q2 FY2025-2026 is 2,025.58 million
- 4
Earnings per equity share for continuing operations is 6.27 for both basic and diluted
Informational and educational content only. Not investment advice.